Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

  • Bernardo-Faura, Martí
  • Rinas, Melanie
  • Wirbel, Jakob
  • Pertsovskaya, Inna
  • Pliaka, Vicky
  • Messinis, Dimitris E.
  • Vila, Gemma
  • Sakellaropoulos, Theodore
  • Faigle, Wolfgang
  • Stridh, Pernilla
  • Behrens, Janina R.
  • Olsson, Tomas
  • Martin, Roland
  • Paul, Friedemann
  • Alexopoulos, Leonidas G.
  • Villoslada, Pablo
  • Sáez-Rodríguez, Julio
This work was supported by the European Union 7FP-Programme (CombiMS, grant No 305397) and the European Sys4MS project (Horizon2020: Eracosysmed: ID-43). RM and the Section for Neuroimmunology and MS Research, University Zurich (UZH), have been supported by a European Research Council Advanced Grant (ERC 340733-HLA-DR15 in MS), by a Clinical Research Priority Project - disease heterogeneity of MS (CRPPMS; UZH), by the Swiss National Science Foundation and the Swiss MS Society. Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

  • Bernardo-Faura, Martí|||0000-0002-8023-3263
  • Rinas, Melanie
  • Wirbel, Jakob|||0000-0002-4073-3562
  • Pertsovskaya, Inna
  • Pliaka, Vicky
  • Messinis, Dimitris E.
  • Vila, Gemma
  • Sakellaropoulos, Theodore
  • Faigle, Wolfgang
  • Stridh, Pernilla|||0000-0003-4855-0039
  • Behrens, Janina R.
  • Olsson, Tomas
  • Martin, Roland|||0000-0002-0982-1329
  • Paul, Friedemann|||0000-0002-6378-0070
  • Alexopoulos, Leonidas G.
  • Villoslada, P.|||0000-0002-8735-6119
  • Saez-Rodriguez, Julio|||0000-0002-8552-8976
Multiple sclerosis (MS) is a major health problem, leading to a significant disability and patient suffering. Although chronic activation of the immune system is a hallmark of the disease, its pathogenesis is poorly understood, while current treatments only ameliorate the disease and may produce severe side effects. Here, we applied a network-based modeling approach based on phosphoproteomic data to uncover the differential activation in signaling wiring between healthy donors, untreated patients, and those under different treatments. Based in the patient-specific networks, we aimed to create a new approach to identify drug combinations that revert signaling to a healthy-like state. We performed ex vivo multiplexed phosphoproteomic assays upon perturbations with multiple drugs and ligands in primary immune cells from 169 subjects (MS patients, n=129 and matched healthy controls, n=40). Patients were either untreated or treated with fingolimod, natalizumab, interferon-β, glatiramer acetate, or the experimental therapy epigallocatechin gallate (EGCG). We generated for each donor a dynamic logic model by fitting a bespoke literature-derived network of MS-related pathways to the perturbation data. Last, we developed an approach based on network topology to identify deregulated interactions whose activity could be reverted to a "healthy-like" status by combination therapy. The experimental autoimmune encephalomyelitis (EAE) mouse model of MS was used to validate the prediction of combination therapies. Analysis of the models uncovered features of healthy-, disease-, and drug-specific signaling networks. We predicted several combinations with approved MS drugs that could revert signaling to a healthy-like state. Specifically, TGF-β activated kinase 1 (TAK1) kinase, involved in Transforming growth factor β-1 proprotein (TGF-β), Toll-like receptor, B cell receptor, and response to inflammation pathways, was found to be highly deregulated and co-druggable with all MS drugs studied. One of these predicted combinations, fingolimod with a TAK1 inhibitor, was validated in an animal model of MS. Our approach based on donor-specific signaling networks enables prediction of targets for combination therapy for MS and other complex diseases.